China Inc. Shines In Latest Batch Of Approvals
Global-First PD-1 Nod For Nasopharyngeal Cancer In China
Executive Summary
Chinese domestic firms have gained a flurry of novel drug approvals at home, including the first globally for an anti-PD-1 antibody for nasopharyngeal carcinoma.